ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines
Authors:
Open Access
- 16 January 2024
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 15 (1) , 1-18
Abstract
Https://doi.org/10.18632/oncotarget.28551 Mathew Lozinski, Nikola A. Bowden, Moira C. Graves, Michael Fay, Bryan W. Day, Brett W. Stringer, Paul A. TooneyKeywords
All Related Versions
This publication has 60 references indexed in Scilit:
- STING: infection, inflammation and cancerNature Reviews Immunology, 2015
- Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibitionOncotarget, 2015
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency ModelComputational and Structural Biotechnology Journal, 2015
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor MicroenvironmentCancer Immunology Research, 2014
- Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer CellsPLOS ONE, 2013
- admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET PropertiesJournal of Chemical Information and Modeling, 2012
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell linesCancer Cell, 2006
- In vitro evaluation of temozolomide combined with X-irradiationAnti-Cancer Drugs, 1997